What's Happening?
Agendia, Inc. has announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to recognize MammaPrint and BluePrint tests for guiding anthracycline use in HR+/HER2- early-stage breast cancer. The update is
based on real-world evidence from the FLEX Study, which showed that patients with MammaPrint High Risk 2 and BluePrint Luminal B tumors benefit significantly from anthracycline-based chemotherapy. The study involved 1261 patients and demonstrated that those treated with anthracyclines had better invasive disease-free survival rates compared to those who did not receive this treatment. This update aims to enhance personalized treatment decisions for breast cancer patients.
Why It's Important?
The NCCN guideline update represents a significant advancement in precision oncology, allowing for more tailored treatment plans for breast cancer patients. By identifying which patients are most likely to benefit from anthracycline-based therapy, the guidelines can help optimize treatment efficacy while minimizing unnecessary exposure to the potential side effects of chemotherapy. This personalized approach could improve patient outcomes and reduce the risk of long-term complications associated with chemotherapy, such as cardiotoxicity and secondary leukemia. The update underscores the importance of genomic testing in informing clinical decisions and advancing cancer care.
What's Next?
Agendia plans to continue its research efforts through the FLEX Study, which aims to generate further real-world evidence on the use of genomic assays in breast cancer treatment. The company will also focus on expanding its partnerships with oncology centers worldwide to enhance the adoption of precision genomics in clinical practice. Future studies may explore additional genomic markers and treatment strategies to further refine personalized cancer care. The ongoing research and collaboration efforts are expected to contribute to the development of more effective and individualized treatment options for breast cancer patients.
